Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9985204 | 0.93 | HSF1 (0.57) | HSF1SRCHTR2AHTR2CTRPV1 | |
| SCHEMBL6788873 | 0.89 | HSF1 (0.53) | HSF1TRPV1PDGFRBPDGFRAMAPT | |
| SCHEMBL6787557 | 0.86 | HSF1 (0.52) | HSF1TRPV1PDGFRBPDGFRAMAPT | |
| SCHEMBL6786712 | 0.85 | HSF1 (0.49) | HSF1TRPV1PDGFRBPDGFRAMAPT | |
| SCHEMBL6793338 | 0.81 | HSF1 (0.64) | HSF1TRPV1PDGFRBPDGFRAEGFR | |
| SCHEMBL6789036 | 0.78 | HSF1 (0.62) | HSF1 | |
| SCHEMBL6787562 | 0.78 | HSF1 (0.59) | HSF1TRPV1EGFRPOLB | |
| SCHEMBL9986111 | 0.76 | HSF1 (0.52) | HSF1HTR2APDGFRBPDGFRAMAPT | |
| SCHEMBL9984487 | 0.76 | HSF1 (0.59) | HSF1POLB | |
| SCHEMBL6789725 | 0.75 | HSF1 (0.59) | HSF1MAPTL3MBTL1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306641-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | claimed |
| US-20110306641-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| CN-1610667-A | 3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives | DONG WHA PHARM IND CO LTD (KR) | 2005-04-27 | — | — | CN | disclosed |
| US-6743795-B1 | INHIBITORS FOR HEPATITIS B AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) BECAUSE THEY INTERFERE WITH REMOVAL OF RNA STRAND FROM RNA-DNA HYBRID FORMED DURING THE REVERSE TRANSCRIPTION OF VIRAL RNA TO DNA | DONG WHA PHARM. IND. CO. LTD. (KR) | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306641-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL PREPARATION INCLUDING SAME | PTMS, NOS3, NOS1 | HSF1 4573/4885SRC 1882/4885HTR2A 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.